Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095082 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 447
- Enrollment target
NCT00095082 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 447 participants.
The verdict
NCT00095082, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 447 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
Interventions
- DRUG insulin aspart
- DRUG insulin glargine
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 447 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095082
The ClinicalTrials.gov registry entry for NCT00095082 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT00095082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095082 about?
NCT00095082 is a clinical study titled "Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes". This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
What is the current status of trial NCT00095082?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 447 participants. The study started on 2004-09. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00095082?
The interventions under investigation include: insulin aspart (DRUG), insulin glargine (DRUG), insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00095082?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.